Tvardi Therapeutics (NASDAQ:TVRD) Now Covered by Chardan Capital

Analysts at Chardan Capital began coverage on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research report issued to clients and investors on Tuesday, MarketBeat Ratings reports. The brokerage set a “buy” rating on the stock.

Other equities research analysts have also recently issued reports about the stock. BTIG Research cut their price objective on shares of Tvardi Therapeutics to $5.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. UBS Group upgraded shares of Tvardi Therapeutics to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. Raymond James Financial upgraded shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective for the company in a research report on Wednesday, July 8th. Lucid Cap Mkts upgraded shares of Tvardi Therapeutics to a “strong-buy” rating in a research report on Tuesday, September 8th. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, October 12th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $9.40.

Tvardi Therapeutics Trading Up 3.5%

NASDAQ:TVRD opened at $1.00 on Tuesday. The company’s 50-day moving average price is $1.55 and its 200-day moving average price is $2.46. The company has a market cap of $13.39 million, a P/E ratio of -0.36 and a beta of 0.38. Tvardi Therapeutics has a twelve month low of $0.93 and a twelve month high of $6.13.

Tvardi Therapeutics (NASDAQ:TVRD) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.65) by ($0.04). On average, analysts expect that Tvardi Therapeutics will post -2.35 earnings per share for the current year.

Institutional Investors Weigh In On Tvardi Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. GSA Capital Partners LLP acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at about $34,000. Susquehanna International Group LLP acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at about $63,000. Finally, BlackRock Inc. acquired a new stake in shares of Tvardi Therapeutics during the second quarter valued at about $181,000. 44.66% of the stock is currently owned by institutional investors and hedge funds.

Tvardi Therapeutics Company Profile

Tvardi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases driven by abnormal STAT3 signaling. The company’s research is centered on inhibiting STAT3, a protein involved in tumor growth, immune evasion, inflammation and resistance to existing treatments.

Tvardi’s lead investigational product is TTI-101, an oral, small-molecule STAT3 inhibitor being evaluated in clinical studies for advanced solid tumors. The company is investigating the therapy both as a standalone treatment and in combination with other anticancer therapies, with the goal of addressing cancers in which STAT3 activity contributes to disease progression.

Tvardi Therapeutics is headquartered in Houston, Texas, and its development programs are focused on advancing targeted medicines through clinical testing.